Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Shareholder Meeting (November 2018)
17 slides from Optiscan Imaging's shareholder meeting presentation, November 2018
Slide 1: Annual General Meeting 2018
Ly (@ptiscan Ss Annual General Meeting 2018
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Optiscan Imaging Limited (OIL). This presentation contains summary information about OIL which is current as at 30 November 2018. Neither the OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation
Slide 3: Disclaimer
Disclaimer Past performance The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of OIL's views on its future performance or condition. Actual results could differ materially
Slide 4: Presentation Contents
Presentation Contents • Overview • Strategic Focus • Carl Zeiss Meditec Collaboration Agreement • FIVE2 (ViewnVivo) Re-Branding • FIVE2 (ViewnVivo) Australian Pre-Clinical and Translational Activities • FIVE2 New Application Areas of Interest • Breast Cancer Surgical Margin Trial • Financials • Outl
Slide 5: Overview
Overview • 2018 has been a year of change but also significant progress for Optiscan • Board and Management Changes in the first half of the year • Retention of Key Management in R&D, Quality and Applications • FDA 510(k) Clearance and CE Mark for Carl Zeiss Meditec CONVIVO • Receipt of ISO13485 cer
Slide 6: Strategic Focus
Strategic Focus • Continued support and shift to production focus as part of CZM collaboration agreement • Focus on additional clinical application areas to diversify revenue sources & increase revenue streams over medium to longer term: ➢ Commencement of Breast Cancer Surgical Margin trial ➢ Invest
Slide 7: Carl Zeiss Meditec (CZM) Collaboration Agreement
Carl Zeiss Meditec (CZM) Collaboration Agreement • Completion of development and integration with CZM and receipt of accompanying milestone payments • CE Mark and FDA 510(k) regulatory approvals received by CZM for CONVIVO • On-going CZM funded Research and Development enhancements • CZM advises com
Slide 8: FIVE2 (ViewnVivo) Re-Branding
FIVE2 (ViewnVivo) Re-Branding FIVE (Fluoresence InVivo Endomicroscopy) • Multi-faceted re-branding of FIVE2 (ViewnVivo) • Represents next-generation technological advance of the FIVE1 system • New website cornerstone of re-branding (www.optiscan.com) • Updated publication list including filtered sea
Slide 9: FIVE2 (ViewnVivo) Australian Pre-Clinical and Translational Activities
FIVE2 (ViewnVivo) Australian Pre-Clinical and Translational Activities • Attending conferences and conducting industry workshops in Brisbane (March 2019) and Melbourne (September 2019) • Conducted presentations at medical and government research institutions in Melbourne, Sydney, Brisbane and Adelai
Slide 10: FIVE2 New Application Areas of Interest
FIVE2 New Application Areas of Interest • Cellular cultures and organoids • Complex, self organising 3D tissue cultures. • Used for cancer research, drug screening, personalised medicine. Dr Zay Yar Oo, CSIRO Maximum intensity projection of cultured human dermal fibroblasts stained with Alexa-488-ph
Slide 11: FIVE2 New Application Areas of Interest- Equine Veterinary application
FIVE2 New Application Areas of Interest- Equine Veterinary application Real-time-in Vivo Microscopic Imaging of Equine Endometrium Using Confocal Laser Endomicroscopy: Preliminary Observations and Feasibility Study Poor reproductive performance in the mare has major financial implications for the eq
Slide 12: FIVE2 New Application Areas of Interest- Sterilisable Sheath Option
FIVE2 New Application Areas of Interest- Sterilisable Sheath Option • Opportunity for longitudinal studies • Ability to re-sterilise the sheath enabling lower cost reusable sheath • Initial focus on pre-clinical and translational applications • Testing procedures and protocols being arranged
Slide 13: Breast Cancer Trial
Normal Breast Tissue Breast Cancer Trial • Assessment of Breast Cancer Surgical Margin with Confocal Laser Endomicroscopy • Goal: assist breast surgeons and pathologists to provide real-time determination of required surgical margin • Benefits: Reduce risk of residual tumour, need for repeat surgery
Slide 14: CLE Breast Cancer Atlas: Comparison CLE & Histopathology
CLE Breast Cancer Atlas: Comparison CLE & Histopathology Breast Cancer Fibrous Tissue Normal Breast
Slide 15: Financials
Financials • FY2018 Revenue of $2.2m (FY2017: $1.35m) • FY2018 Loss before Income tax of ($2.04m) (FY2017: (Loss of $2.94m)) • Reduction in recurring costs of in excess of $1m per annum through a reduction in employee and board numbers, alteration of third party arrangements, reduced travel and inve
Slide 16: Outlook
Outlook • Focus on development of additional clinical, veterinary and pre-clinical applications ➢ Complete initial Stage and progress to next Stages of Breast Cancer Surgical Margin trial ➢ Continue evaluation of new clinical applications with leading North American clinical and research institution
Slide 17: Thank you for your attendance
Thank you for your attendance
Optiscan Imaging — Shareholder Meeting (November 2018) on 6ix